Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Jun 2011
ReviewQuality of reporting in randomized controlled trials conducted in China on the treatment of cancer pain.
Research in China has been rapidly gaining momentum, but as yet there is no systematic evaluation of quality of reporting in randomized controlled trials (RCTs) on the treatment of cancer pain conducted in China. Therefore, an assessment in this field is an imperative issue. ⋯ The quality of reporting in RCTs on the treatment of cancer pain conducted in China needs to be improved. Three critical steps should be strictly conducted including randomization, blinding and follow-up. Reporting of RCTs in this field conducted in China should meet and keep up with the standards of CONSORT statement.
-
Renal cell carcinoma (RCC) is the most common malignant neoplasm of the kidney, and sarcomatoid RCC is an aggressive and lethal variant. Sarcomatoid features can be seen in all types of RCC and do not constitute a separate histologic type. ⋯ Most systemic therapies developed for metastatic RCC are less effective in sarcomatoid RCC, although some of the cytotoxic drugs may actually be more effective for sarcomatoid RCC because of its rapid rate of proliferation. Several ongoing prospective clinical trials are investigating new drug combinations for this disease.